US 11,753,439 B2
Giardia recombinant antigens, purification of polyclonal anti-Giardia IgG and IgY antibodies and Giardia detection
Ángela Liliana Albarracín Cárdenas, Bogotá (CO); Adriana Arévalo Jamaica, Bogotá (CO); Sofía Duque Beltrán, Bogotá (CO); Fabio Leonardo Quintero Vargas, Bogotá (CO); and Cesar Augusto Ramírez Segura, Bogotá (CO)
Assigned to Instituto Nacional de Salud, Bogotá (CO)
Appl. No. 16/619,719
Filed by INSTITUTO NACIONAL DE SALUD, Bogota (CO)
PCT Filed Dec. 18, 2017, PCT No. PCT/IB2017/058083
§ 371(c)(1), (2) Date Jan. 24, 2020,
PCT Pub. No. WO2019/021049, PCT Pub. Date Jan. 31, 2019.
Claims priority of application No. NC2017/0007377 (CO), filed on Jul. 25, 2017.
Prior Publication US 2020/0354401 A1, Nov. 12, 2020
Int. Cl. C07K 1/22 (2006.01); C07K 16/02 (2006.01); G01N 33/569 (2006.01)
CPC C07K 1/22 (2013.01) [C07K 16/02 (2013.01); G01N 33/569 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A kit for detecting Giardia antigens consisting of the following components: a first capture consisting of purified polyclonal anti-Giardia IgG or anti-Giardia IgY antibodies, and a second capture consisting of purified polyclonal anti-Giardia IgY or anti-Giardia IgG antibodies; provided that the first capture and the second capture are not the same; a solid matrix selected from polystyrene plates or nitrocellulose membrane (MNC); a blocking solution; phosphate buffer saline −0.1% Polysorbate 20 pH 7.2 (PBS-T); a conjugate of anti-IgY or anti-IgG antibodies bound to a reporter; and optionally a detection reagent; wherein if the second capture is a polyclonal anti-Giardia IgY antibody, the conjugate is a conjugate of anti-IgY; or wherein if the second capture is a polyclonal anti-Giardia IgG antibody, and the conjugate is a conjugate of anti-IgG; and wherein the purified polyclonal anti-Giardia IgG antibodies and the polyclonal anti-Giardia IgY antibodies are purified by affinity chromatography with the recombinant Giardia antigens Alpha Giardin 7.3, Kinesin 3 and Cyst wall protein 1 (CWP1).